73 results on '"Kidron H"'
Search Results
2. THE NATIVE STRUCTURES OF SOLUBLE HUMAN PRIMARY AMINE OXIDASE AOC3
- Author
-
Elovaara, H., primary, Kidron, H., additional, Parkash, V., additional, Nymalm, Y., additional, Bligt, E., additional, Ollikka, P., additional, Smith, D.J., additional, Pihlavisto, M., additional, Salmi, M., additional, Jalkanen, S., additional, and Salminen, T.A., additional
- Published
- 2011
- Full Text
- View/download PDF
3. THE CRYSTAL STRUCTURE OF HUMAN SOLUBLE PRIMARY AMINE OXIDASE AOC3 IN THE OFF-COPPER CONFORMATION
- Author
-
Elovaara, H., primary, Kidron, H., additional, Parkash, V., additional, Nymalm, Y., additional, Bligt, E., additional, Ollikka, P., additional, Smith, D.J., additional, Pihlavisto, M., additional, Salmi, M., additional, Jalkanen, S., additional, and Salminen, T.A., additional
- Published
- 2011
- Full Text
- View/download PDF
4. Functional Classification of Amino Acid Decarboxylases from the Alanine Racemase Structural Family by Phylogenetic Studies
- Author
-
Kidron, H., primary, Repo, S., additional, Johnson, M. S., additional, and Salminen, T. A., additional
- Published
- 2006
- Full Text
- View/download PDF
5. X-ray structure of bovine GLTP
- Author
-
Airenne, T.T., primary, Kidron, H., additional, West, G., additional, Nymalm, Y., additional, Nylund, M., additional, Mattjus, P., additional, and Salminen, T.A., additional
- Published
- 2005
- Full Text
- View/download PDF
6. Structural studies on collagen-binding integrin I domains
- Author
-
Viitanen, L., primary, Brandt, A.-M., additional, Kidron, H., additional, Nymalm-Rejström, Y., additional, Airenne, T., additional, and Salminen, T., additional
- Published
- 2004
- Full Text
- View/download PDF
7. Structural studies on human vascular adhesion protein-1
- Author
-
Kidron, H., primary, Nymalm, Y., additional, Söderholm, A., additional, Viitanen, L., additional, Kaukonen, K., additional, Pihlavisto, M., additional, Airenne, T. T., additional, Johnson, M. S., additional, and Salminen, T. A., additional
- Published
- 2004
- Full Text
- View/download PDF
8. Crystallisation and preliminary X-ray analysis of glycolipid transfer protein
- Author
-
Nymalm, Y., primary, West, G., additional, Kidron, H., additional, Airenne, T., additional, Mattjus, P., additional, and Salminen, T., additional
- Published
- 2004
- Full Text
- View/download PDF
9. I domain from human integrin alpha1-beta1
- Author
-
Nymalm, Y., primary, Puranen, J.S., additional, Nyholm, T.K.M., additional, Kapyla, J., additional, Kidron, H., additional, Pentikainen, O., additional, Airenne, T.T., additional, Heino, J., additional, Slotte, J.P., additional, Johnson, M.S., additional, and Salminen, T.A., additional
- Published
- 2004
- Full Text
- View/download PDF
10. Isolation of Intact and Functional Melanosomes from the Retinal Pigment Epithelium
- Author
-
Pelkonen L, Reinisalo M, Emmanuelle Morin-Picardat, Kidron H, and Urtti A
11. Avidin related protein 2 shows unique structural and functional features among the avidin protein family
- Author
-
Salminen Tiina A, Johnson Mark S, Nyholm Thomas KM, Kulomaa Tuomas, Hörhä Jarno, Halling Katrin K, Kidron Heidi, Määttä Juha AE, Hytönen Vesa P, Kulomaa Markku S, and Airenne Tomi T
- Subjects
Biotechnology ,TP248.13-248.65 - Abstract
Abstract Background The chicken avidin gene family consists of avidin and several avidin related genes (AVRs). Of these gene products, avidin is the best characterized and is known for its extremely high affinity for D-biotin, a property that is utilized in numerous modern life science applications. Recently, the AVR genes have been expressed as recombinant proteins, which have shown different biotin-binding properties as compared to avidin. Results In the present study, we have employed multiple biochemical methods to better understand the structure-function relationship of AVR proteins focusing on AVR2. Firstly, we have solved the high-resolution crystal structure of AVR2 in complex with a bound ligand, D-biotin. The AVR2 structure reveals an overall fold similar to the previously determined structures of avidin and AVR4. Major differences are seen, especially at the 1–3 subunit interface, which is stabilized mainly by polar interactions in the case of AVR2 but by hydrophobic interactions in the case of AVR4 and avidin, and in the vicinity of the biotin binding pocket. Secondly, mutagenesis, competitive dissociation analysis and differential scanning calorimetry were used to compare and study the biotin-binding properties as well as the thermal stability of AVRs and avidin. These analyses pinpointed the importance of residue 109 for biotin binding and stability of AVRs. The I109K mutation increased the biotin-binding affinity of AVR2, whereas the K109I mutation decreased the biotin-binding affinity of AVR4. Furthermore, the thermal stability of AVR2(I109K) increased in comparison to the wild-type protein and the K109I mutation led to a decrease in the thermal stability of AVR4. Conclusion Altogether, this study broadens our understanding of the structural features determining the ligand-binding affinities and stability as well as the molecular evolution within the protein family. This novel information can be applied to further develop and improve the tools already widely used in avidin-biotin technology.
- Published
- 2005
- Full Text
- View/download PDF
12. Preincubation-dependent inhibition of organic anion transporting polypeptide 2B1.
- Author
-
Sinokki A, Miinalainen A, Kiander W, and Kidron H
- Subjects
- Humans, HEK293 Cells, Simeprevir pharmacology, Ezetimibe pharmacology, Erlotinib Hydrochloride pharmacology, Ticagrelor pharmacology, Estrone analogs & derivatives, Estrone pharmacology, Organic Anion Transporters antagonists & inhibitors, Organic Anion Transporters metabolism, Atorvastatin pharmacology, Drug Interactions
- Abstract
Preincubation with inhibitor in organic anion transporting polypeptide (OATP) in vitro assays may increase the inhibition potency of inhibitors compared to conventional inhibition assays with only short inhibitor coincubation with substrate. The decrease in IC
50 may affect prediction of drug-drug interactions (DDI) involving these transporters and inhibitors. Only few drugs, however, have been assessed for the preincubation-dependent inhibition of the OATP2B1 transporter. Therefore, we studied the effect of preincubation on OATP2B1 inhibition with five known OATP2B1 inhibitors (atorvastatin, erlotinib, ezetimibe, ticagrelor and simeprevir) in HEK293 cells transiently overexpressing OATP2B1. IC50 values were determined with and without inhibitor preincubation for 20 min with three different OATP2B1 substrates (dibromofluorescein, DBF; 5-carboxyfluorescein, 5-CF; estrone sulfate). Atorvastatin, ezetimibe, and simeprevir displayed more than 2-fold lower IC50 values after preincubation with at least one of the tested substrates. Altogether, 4 out of 15 inhibitor/substrate combinations exhibited more than 2-fold potentiation of IC50 after inhibitor preincubation. In addition, preincubation by itself, without inhibitor present with the substrate, resulted in more than 50% inhibition of OATP2B1-mediated uptake of DBF and/or 5-CF by atorvastatin, ticagrelor and simeprevir. Thus, erlotinib was the only inhibitor with no indication of potentiation of inhibition by preincubation with any of the tested substrates. In conclusion, preincubation resulted in inhibitor- and substrate-dependent inhibition of OATP2B1. These results support the conclusion that to reduce the risk of false negative DDI prediction, preincubation should be considered also in OATP2B1 inhibition assays., Competing Interests: Declaration of competing interest None., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
13. Transporter Protein Expression of Corneal Epithelium in Rabbit and Porcine: Evaluation of Models for Ocular Drug Transport Study.
- Author
-
Ramsay E, Montaser AB, Niitsu K, Urtti A, Auriola S, Huttunen KM, Uchida Y, Kidron H, and Terasaki T
- Subjects
- Animals, Rabbits, Swine, Biological Transport, Membrane Transport Proteins metabolism, Administration, Ophthalmic, Epithelium, Corneal metabolism, Proteomics methods
- Abstract
The transcorneal route is the main entry route for drugs to the intraocular parts, after topical administration. The outer surface, the corneal epithelium (CE), forms the rate-limiting barrier for drug permeability. Information about the role and protein expression of drug and amino acid transporter proteins in the CE is sparse and lacking. The aim of our study was to characterize transporter protein expression in rabbit and porcine CE to better understand potential drug and nutrient absorption after topical administration. Proteins, mainly Abc and Slc transporters, were characterized with quantitative targeted absolute proteomics and global untargeted proteomics methods. In the rabbit CE, 24 of 48 proteins were detected in the targeted approach, and 21 of these were quantified. In the porcine CE, 26 of 58 proteins were detected in the targeted approach, and 20 of these were quantified. Among these, 15 proteins were quantified in both animals: 4f2hc (Slc3a2), Aqp0, Asct1 (Slc1a4), Asct2 (Slc1a5), Glut1 (Slc2a1), Hmit (Slc2a13), Insr, Lat1 (Slc7a5), Mct1 (Slc16a1), Mct2 (Slc16a7), Mct4 (Slc16a3), Mrp 4 (Abcc4), Na
+ /K+ -ATPase, Oatp3a1 (Slco3a1), and Snat2 (Slc38a2). Overall, the global proteomics results supported the targeted proteomics results. Organic anion transporting polypeptide Oatp3a1 was detected and quantified for the first time in both rabbit (1.4 ± 0.4 fmol/cm2 ) and porcine (11.1 ± 5.3 fmol/cm2 ) CE. High expression levels were observed for L-type amino acid transporter, Lat1, which was quantified with newly selected extracellular domain peptides in rabbit (48.9 ± 11.8 fmol/cm2 ) and porcine (37.6 ± 11.5 fmol/cm2 ) CE. The knowledge of transporter protein expression in ocular barriers is a key factor in the successful design of new ocular drugs, pharmacokinetic modeling, understanding ocular diseases, and the translation to human.- Published
- 2024
- Full Text
- View/download PDF
14. Monoacylglycerol Lipase Inhibitor JJKK048 Ameliorates ABCG2 Transporter-Mediated Regorafenib Resistance Induced by Hypoxia in Triple Negative Breast Cancer Cells.
- Author
-
Puris E, Petralla S, Auriola S, Kidron H, Fricker G, and Gynther M
- Subjects
- Humans, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Cell Line, Tumor, Drug Resistance, Neoplasm, Hypoxia, Monoacylglycerol Lipases metabolism, Monoacylglycerol Lipases pharmacology, Neoplasm Proteins metabolism, Triple Negative Breast Neoplasms drug therapy, Piperidines pharmacology, Piperidines therapeutic use, Triazoles pharmacology, Triazoles therapeutic use
- Abstract
Triple negative breast cancer (TNBC) is among the most aggressive and deadly cancer subtypes. Intra-tumoral hypoxia is associated with aggressiveness and drug resistance in TNBC. One of the underlying mechanisms of hypoxia-induced drug resistance is the elevated expression of efflux transporters such as breast cancer resistant protein (ABCG2). In the present study, we investigated the possibility of ameliorating ABCG2-mediated drug resistance in hypoxic TNBC cells by monoacylglycerol lipase (MAGL) inhibition and the consequent downregulation of ABCG2 expression. The effect of MAGL inhibition on ABCG2 expression, function, and efficacy of regorafenib, an ABCG2 substrate was investigated in cobalt dichloride (CoCl
2 ) induced pseudohypoxic TNBC (MDA-MB-231) cells, using quantitative targeted absolute proteomics, qRT-PCR, anti-cancer drug accumulation in the cells, cell invasiveness and resazurin-based cell viability assays. Our results showed that hypoxia-induced ABCG2 expression led to low regorafenib intracellular concentrations, reduced the anti-invasiveness efficacy, and elevated half maximal inhibitory concentration (IC50 ) of regorafenib in vitro MDA-MB-231 cells. MAGL inhibitor, JJKK048, reduced ABCG2 expression, increased regorafenib cell accumulation, which led to higher regorafenib efficacy. In conclusion, hypoxia-induced regorafenib resistance due to ABCG2 over-expression in TNBC cells can be ameliorated by MAGL inhibition., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results., (Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
15. In vitro identification of decreased function phenotype ABCG2 variants.
- Author
-
Suominen L, Sjöstedt N, Vellonen KS, Gynther M, Auriola S, and Kidron H
- Subjects
- Humans, ATP Binding Cassette Transporter, Subfamily G, Member 2 genetics, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Biological Transport, HEK293 Cells, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Phenotype, Polymorphism, Single Nucleotide
- Abstract
Reduced activity of efflux transporter ABCG2, caused e.g., by inhibition or decreased function genetic variants, can increase drug absorption and plasma levels. ABCG2 has one clinically significant single nucleotide variant Q141K (c.421C>A), which leads to decreased protein levels and transport activity. In addition to Q141K, ABCG2 has over 500 rare (<1% minor allele frequency) nonsynonymous variants, but their functionality remains unknown. We studied the transport activity and abundance of 30 rare ABCG2 variants. The variants were transiently expressed in HEK293 cells. Transport activity and protein abundance were measured from inside-out crude membrane vesicles. Results were normalised to the reference ABCG2, while Q141K was used to categorise variants into decreased and normal function phenotypes based on their apparent transport activity. Fourteen variants (G80E, D128V, T434M, Q437R, C438R, C438W, C438Y, L479S, P480L, S486N, T512N, S519P, G553D and K647E) had similar or lower apparent transport activity than Q141K and thus were categorised as having a decreased function phenotype. Protein abundance could not explain all of the observed changes in transport activity: Only six variants (D128V, Q437R, C438R, S519P, G553D, and K647E) had similar or lower abundance compared to Q141K. The decreased function variants may increase systemic drug exposure and therefore cause interindividual variability in pharmacokinetics. In the future, in vitro phenotype classification may help to design personalised drug treatments., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
16. Selective drug delivery to the retinal cells: Biological barriers and avenues.
- Author
-
Ramsay E, Lajunen T, Bhattacharya M, Reinisalo M, Rilla K, Kidron H, Terasaki T, and Urtti A
- Subjects
- Humans, Retina metabolism, Pharmaceutical Preparations, Intravitreal Injections, Drug Delivery Systems methods, Retinal Diseases drug therapy, Retinal Diseases metabolism
- Abstract
Retinal drug delivery is a challenging, but important task, because most retinal diseases are still without any proper therapy. Drug delivery to the retina is hampered by the anatomical and physiological barriers resulting in minimal bioavailability after topical ocular and systemic administrations. Intravitreal injections are current method-of-choice in retinal delivery, but these injections show short duration of action for small molecules and low target bioavailability for many protein, gene based drugs and nanomedicines. State-of-art delivery systems are based on prolonged retention, controlled drug release and physical features (e.g. size and charge). However, drug delivery to the retina is not cell-specific and these approaches do not facilitate intracellular delivery of modern biological drugs (e.g. intracellular proteins, RNA based medicines, gene editing). In this focused review we highlight biological factors and mechanisms that form the basis for the selective retinal drug delivery systems in the future. Therefore, we are presenting current knowledge related to retinal membrane transporters, receptors and targeting ligands in relation to nanomedicines, conjugates, extracellular vesicles, and melanin binding. These issues are discussed in the light of retinal structure and cell types as well as future prospects in the field. Unlike in some other fields of targeted drug delivery (e.g. cancer research), selective delivery technologies have been rarely studied, even though cell targeted delivery may be even more feasible after local administration into the eye., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
17. Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction?
- Author
-
Lehtisalo M, Kiander W, Filppula AM, Deng F, Kidron H, Korhonen M, Sinkko J, Koivula K, and Niemi M
- Subjects
- United States, Humans, Female, Rosuvastatin Calcium adverse effects, Rosuvastatin Calcium pharmacokinetics, Ticagrelor adverse effects, ATP Binding Cassette Transporter, Subfamily G, Member 2, Neoplasm Proteins metabolism, Drug Interactions, Organic Anion Transporters metabolism, Rhabdomyolysis chemically induced, Breast Neoplasms drug therapy
- Abstract
We present 3 patients diagnosed with rhabdomyolysis 1-6 months after the initiation of concomitant rosuvastatin and ticagrelor medication. A literature review and Food and Drug Administration adverse event reporting system revealed >40 reports of rhabdomyolysis during concomitant ticagrelor and rosuvastatin, including 3 with a fatal outcome. We show that ticagrelor inhibits breast cancer resistance protein-, organic anion transporting polypeptide (OATP) 1B1-, 1B3- and 2B1-mediated transport of rosuvastatin in vitro with half-maximal unbound inhibitory concentrations of 0.36, 4.13, 7.5 and 3.26 μM, respectively. A static drug interaction model predicted that ticagrelor may inhibit intestinal breast cancer resistance protein and thus increase rosuvastatin plasma exposure 2.1-fold, whereas the OATP-mediated hepatic uptake of rosuvastatin should not be inhibited due to relatively low portal ticagrelor concentrations. Taken together, concomitant use of ticagrelor with rosuvastatin may increase the systemic exposure to rosuvastatin and the risk of rosuvastatin-induced rhabdomyolysis. Further studies are warranted to investigate the potential pharmacokinetic interaction between ticagrelor and rosuvastatin in humans., (© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
- Published
- 2023
- Full Text
- View/download PDF
18. Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder.
- Author
-
Häkkinen K, Kiander W, Kidron H, Lähteenvuo M, Urpa L, Lintunen J, Vellonen KS, Auriola S, Holm M, Lahdensuo K, Kampman O, Isometsä E, Kieseppä T, Lönnqvist J, Suvisaari J, Hietala J, Tiihonen J, Palotie A, Ahola-Olli AV, and Niemi M
- Subjects
- Humans, Finland, HEK293 Cells, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Rosuvastatin Calcium, Liver-Specific Organic Anion Transporter 1 genetics, Psychotic Disorders
- Abstract
Variants in the SLCO1B1 (solute carrier organic anion transporter family member 1B1) gene encoding the OATP1B1 (organic anion transporting polypeptide 1B1) protein are associated with altered transporter function that can predispose patients to adverse drug effects with statin treatment. We explored the effect of six rare SLCO1B1 single nucleotide variants (SNVs) occurring in Finnish individuals with a psychotic disorder on expression and functionality of the OATP1B1 protein. The SUPER-Finland study has performed exome sequencing on 9381 individuals with at least one psychotic episode during their lifetime. SLCO1B1 SNVs were annotated with PHRED-scaled combined annotation-dependent (CADD) scores and the Ensembl variant effect predictor. In vitro functionality studies were conducted for the SNVs with a PHRED-scaled CADD score of >10 and predicted to be missense. To estimate possible changes in transport activity caused by the variants, transport of 2',7'-dichlorofluorescein (DCF) in OATP1B1-expressing HEK293 cells was measured. According to the findings, additional tests with rosuvastatin and estrone sulfate were conducted. The amount of OATP1B1 in crude membrane fractions was quantified using a liquid chromatography tandem mass spectrometry-based quantitative targeted absolute proteomics analysis. Six rare missense variants of SLCO1B1 were identified in the study population, located in transmembrane helix 3: c.317T>C (p.106I>T), intracellular loop 2: c.629G>T (p.210G>V), c.633A>G (p.211I>M), c.639T>A (p.213N>L), transmembrane helix 6: 820A>G (p.274I>V), and the C-terminal end: 2005A>C (p.669N>H). Of these variants, SLCO1B1 c.629G>T (p.210G>V) resulted in the loss of in vitro function, abolishing the uptake of DCF, estrone sulfate, and rosuvastatin and reducing the membrane protein expression to 31% of reference OATP1B1. Of the six rare missense variants, SLCO1B1 c.629G>T (p.210G>V) causes a loss of function of OATP1B1 transport in vitro and severely decreases membrane protein abundance. Carriers of SLCO1B1 c.629G>T might be susceptible to altered pharmacokinetics of OATP1B1 substrate drugs and might have increased likelihood of adverse drug effects such as statin-associated musculoskeletal symptoms.
- Published
- 2023
- Full Text
- View/download PDF
19. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs.
- Author
-
Deng F, Sjöstedt N, Santo M, Neuvonen M, Niemi M, and Kidron H
- Subjects
- Humans, Female, Pharmaceutical Preparations, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Vemurafenib, Neoplasm Proteins metabolism, ATP-Binding Cassette Transporters metabolism, Drug Interactions, Biological Transport, Dabigatran, Breast Neoplasms
- Abstract
Drug-drug interactions (DDIs) are a major concern for the safe use of medications. Breast cancer resistance protein (BCRP) is a clinically relevant ATP-binding cassette (ABC) transporter for drug disposition. Inhibition of BCRP increases the plasma concentrations of BCRP substrate drugs, which potentially could lead to adverse drug reactions. The aim of the present study was to identify BCRP inhibitors amongst a library of 232 commonly used drugs and anticancer drugs approved by the United States Food and Drug Administration (FDA). BCRP inhibition studies were carried out using the vesicular transport assay. We found 75 drugs that reduced the relative transport activity of BCRP to less than 25% of the vehicle control and were categorized as strong inhibitors. The concentration required for 50% inhibition (IC
50 ) was determined for 13 strong inhibitors that were previously poorly characterized for BCRP inhibition. The IC50 ranged from 1.1 to 11 µM, with vemurafenib, dabigatran etexilate and everolimus being the strongest inhibitors. According to the drug interaction guidance documents from the FDA and the European Medicines Agency (EMA), in vivo DDI studies are warranted if the theoretical intestinal luminal concentration of a drug exceeds its IC50 by tenfold. Here, the IC50 values for eight of the drugs were 100-fold lower than their theoretical intestinal luminal concentration. Moreover, a mechanistic static model suggested that vemurafenib, bexarotene, dabigatran etexilate, rifapentine, aprepitant, and ivacaftor could almost fully inhibit intestinal BCRP, increasing the exposure of concomitantly administered rosuvastatin over 90%. Therefore, clinical studies are warranted to investigate whether these drugs cause BCRP-mediated DDIs in humans., Competing Interests: Declaration of Competing Interest None., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
20. Functional in vitro characterization of SLCO1B1 variants and simulation of the clinical pharmacokinetic impact of impaired OATP1B1 function.
- Author
-
Kiander W, Sjöstedt N, Manninen R, Jaakkonen L, Vellonen KS, Neuvonen M, Niemi M, Auriola S, and Kidron H
- Subjects
- Chromatography, Liquid, HEK293 Cells, Humans, Liver-Specific Organic Anion Transporter 1 genetics, Liver-Specific Organic Anion Transporter 1 metabolism, Rosuvastatin Calcium, Organic Anion Transporters genetics, Tandem Mass Spectrometry
- Abstract
Organic Anion Transporting Polypeptide 1B1 is important to the hepatic elimination and distribution of many drugs. If OATP1B1 function is decreased, it can increase plasma exposure of e.g. several statins leading to increased risk of muscle toxicity. First, we examined the impact of three naturally occurring rare variants and the frequent SLCO1B1 c.388A>G variant on in vitro transport activity with cellular uptake assay using two substrates: 2', 7'-dichlorofluorescein (DCF) and rosuvastatin. Secondly, LC-MS/MS based quantitative targeted absolute proteomics measured the OATP1B1 protein abundance in crude membrane fractions of HEK293 cells over-expressing these single nucleotide variants. Additionally, we simulated the effect of impaired OATP1B1 function on rosuvastatin pharmacokinetics to estimate the need for genotype-guided dosing. R57Q impaired DCF and rosuvastatin transport significantly yet did not change protein expression considerably, while N130D and N151S did not alter activity but increased protein expression. R253Q did not change protein expression but reduced DCF uptake and increased rosuvastatin K
m . Based on pharmacokinetic simulations, doses of 30 mg (with 50% OATP1B1 function) and 20 mg (with 0% OATP1B1 function) result in plasma exposure similar to 40 mg dose (with 100% OATP1B1 function). Therefore dose reductions might be considered to avoid increased plasma exposure caused by function-impairing OATP1B1 genetic variants, such as R57Q., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
21. The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates.
- Author
-
Järvinen E, Deng F, Kiander W, Sinokki A, Kidron H, and Sjöstedt N
- Abstract
Glucuronidation and sulfation are the most typical phase II metabolic reactions of drugs. The resulting glucuronide and sulfate conjugates are generally considered inactive and safe. They may, however, be the most prominent drug-related material in the circulation and excreta of humans. The glucuronide and sulfate metabolites of drugs typically have limited cell membrane permeability and subsequently, their distribution and excretion from the human body requires transport proteins. Uptake transporters, such as organic anion transporters (OATs and OATPs), mediate the uptake of conjugates into the liver and kidney, while efflux transporters, such as multidrug resistance proteins (MRPs) and breast cancer resistance protein (BCRP), mediate expulsion of conjugates into bile, urine and the intestinal lumen. Understanding the active transport of conjugated drug metabolites is important for predicting the fate of a drug in the body and its safety and efficacy. The aim of this review is to compile the understanding of transporter-mediated disposition of phase II conjugates. We review the literature on hepatic, intestinal and renal uptake transporters participating in the transport of glucuronide and sulfate metabolites of drugs, other xenobiotics and endobiotics. In addition, we provide an update on the involvement of efflux transporters in the disposition of glucuronide and sulfate metabolites. Finally, we discuss the interplay between uptake and efflux transport in the intestine, liver and kidneys as well as the role of transporters in glucuronide and sulfate conjugate toxicity, drug interactions, pharmacogenetics and species differences., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Järvinen, Deng, Kiander, Sinokki, Kidron and Sjöstedt.)
- Published
- 2022
- Full Text
- View/download PDF
22. The Effect of Single Nucleotide Variations in the Transmembrane Domain of OATP1B1 on in vitro Functionality.
- Author
-
Kiander W, Vellonen KS, Malinen MM, Gynther M, Hagström M, Bhattacharya M, Auriola S, Koenderink JB, and Kidron H
- Subjects
- Biological Transport, Drug Interactions, Gene Expression, HEK293 Cells, Humans, Liver, Liver-Specific Organic Anion Transporter 1 genetics, Mutation, Polymorphism, Genetic, Tandem Mass Spectrometry, Hydroxymethylglutaryl-CoA Reductase Inhibitors metabolism, Isoquinolines metabolism, Liver-Specific Organic Anion Transporter 1 metabolism, Nucleotides metabolism, Rosuvastatin Calcium metabolism
- Abstract
Purpose: Organic Anion Transporting Polypeptide 1B1 (OATP1B1) mediates hepatic influx and clearance of many drugs, including statins. The SLCO1B1 gene is highly polymorphic and its function-impairing variants can predispose patients to adverse effects. The effects of rare genetic variants of SLCO1B1 are mainly unexplored. We examined the impact of eight naturally occurring rare variants and the well-known SLCO1B1 c.521C > T (V174A) variant on in vitro transport activity, cellular localization and abundance., Methods: Transport of rosuvastatin and 2,7-dichlorofluorescein (DCF) in OATP1B1 expressing HEK293 cells was measured to assess changes in activity of the variants. Immunofluorescence and confocal microscopy determined the cellular localization of OATP1B1 and LC-MS/MS based quantitative targeted absolute proteomics analysis quantified the amount of OATP1B1 in crude membrane fractions., Results: All studied variants, with the exception of P336R, reduced protein abundance to varying degree. V174A reduced protein abundance the most, over 90% compared to wild type. Transport function was lost in G76E, V174A, L193R and R580Q variants. R181C decreased activity significantly, while T345M and L543W retained most of wild type OATP1B1 activity. P336R showed increased activity and H575L decreased the transport of DCF significantly, but not of rosuvastatin. Decreased activity was interrelated with lower absolute protein abundance in the studied variants., Conclusions: Transmembrane helices 2, 4 and 11 appear to be crucial for proper membrane localization and function of OATP1B1. Four of the studied variants were identified as loss-of-function variants and as such could make the individual harboring these variants susceptible to altered pharmacokinetics and adverse effects of substrate drugs., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
23. Food Additives as Inhibitors of Intestinal Drug Transporter OATP2B1.
- Author
-
Tikkanen A, Pierrot E, Deng F, Sánchez VB, Hagström M, Koenderink JB, and Kidron H
- Subjects
- Administration, Oral, Estrone administration & dosage, Estrone analogs & derivatives, Estrone pharmacokinetics, Fluoresceins pharmacokinetics, HEK293 Cells, Humans, Organic Anion Transporters metabolism, Recombinant Proteins metabolism, Food Additives pharmacology, Food-Drug Interactions, Intestinal Mucosa metabolism, Organic Anion Transporters antagonists & inhibitors
- Abstract
Food additives are compounds that are added to food and beverage to improve the taste, color, preservation, or composition. Generally, food additives are considered safe for human use due to safety evaluations conducted by food safety authorities and high safety margins applied to permitted usage levels. However, the interaction potential of food additives with simultaneously administered medication has not received much attention. Even though many food additives are poorly absorbed into systemic circulation, high concentrations could exist in the intestinal lumen, making intestinal drug transporters, such as the uptake transporter organic anion transporting polypeptide 2B1 (OATP2B1), a possible site of food additive-drug interactions. In the present work, we aimed to characterize the interaction of a selection of 25 food additives including colorants, preservatives, and sweeteners with OATP2B1 in vitro . In human embryonic kidney 293 (HEK293) cells transiently overexpressing OATP2B1 or control, uptake of dibromofluorescein was studied with and without 50 μM food additive at pH 7.4. As OATP2B1 displays substrate- and pH-dependent transport functions and the intraluminal pH varies along the gastrointestinal tract, we performed the studies also at pH 5.5 using estrone sulfate as an OATP2B1 substrate. Food additives that inhibited OATP2B1-mediated substrate transport by ≥50% were subjected to dose-response studies. Six colorants were identified and validated as OATP2B1 inhibitors at pH 5.5, but only three of these were categorized as inhibitors at pH 7.4. One sweetener was validated as an inhibitor under both assay conditions, whereas none of the preservatives exhibited ≥50% inhibition of OATP2B1-mediated transport. Extrapolation of computed inhibitory constants ( K
i values) to estimations of intestinal food additive concentrations implies that selected colorants could inhibit intestinal OATP2B1 also in vivo . These results suggest that food additives, especially colorants, could alter the pharmacokinetics of orally administered OATP2B1 substrate drugs, although further in vivo studies are warranted to understand the overall clinical consequences of the findings.- Published
- 2020
- Full Text
- View/download PDF
24. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
- Author
-
Deng F, Ghemtio L, Grazhdankin E, Wipf P, Xhaard H, and Kidron H
- Subjects
- ATP Binding Cassette Transporter, Subfamily B antagonists & inhibitors, ATP Binding Cassette Transporter, Subfamily B chemistry, ATP Binding Cassette Transporter, Subfamily B metabolism, ATP Binding Cassette Transporter, Subfamily G, Member 2 antagonists & inhibitors, ATP Binding Cassette Transporter, Subfamily G, Member 2 chemistry, Antineoplastic Agents pharmacology, Biological Transport, Active drug effects, Humans, Ligands, Molecular Docking Simulation, Multidrug Resistance-Associated Protein 2, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Multidrug Resistance-Associated Proteins chemistry, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins chemistry, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Antineoplastic Agents metabolism, Catalytic Domain, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism
- Abstract
ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood-brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure-activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition.
- Published
- 2020
- Full Text
- View/download PDF
25. Human efflux transport of testosterone, epitestosterone and other androgen glucuronides.
- Author
-
Järvinen E, Kidron H, and Finel M
- Subjects
- ATP Binding Cassette Transporter, Subfamily B metabolism, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Biological Transport, Humans, Models, Molecular, Multidrug Resistance-Associated Protein 2, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism, Epitestosterone metabolism, Glucuronides metabolism, Liver metabolism, Testosterone metabolism
- Abstract
Several drug-metabolizing enzymes are known to control androgen homeostasis in humans. UDP-glucuronosyltransferases convert androgens to glucuronide conjugates in the liver and intestine, which enables subsequent elimination of these conjugated androgens via urine. The most important androgen is testosterone, while others are the testosterone metabolites androsterone and etiocholanolone, and the testosterone precursor dehydroepiandrosterone. Epitestosterone is another endogenous androgen, which is included as a crucial marker in urine doping tests. Since glucuronide conjugates are hydrophilic, efflux transporters mediate their excretion from tissues. In this study, we employed the membrane vesicle assay to identify the efflux transporters for glucuronides of androsterone, dehydroepiandrosterone, epitestosterone, etiocholanolone and testosterone. The human hepatic and intestinal transporters MRP2 (ABCC2), MRP3 (ABCC3), MRP4 (ABCC4), BCRP (ABCG2) and MDR1 (ABCB1) were studied in vitro. Of these transporters, only MRP2 and MRP3 transported the androgen glucuronides investigated. In kinetic analyses, MRP3 transported glucuronides of androsterone, epitestosterone and etiocholanolone at low K
m values, between 0.4 and 4 μM, while the Km values for glucuronides of testosterone and dehydroepiandrosterone were 14 and 51 μM, respectively. MRP2 transported the glucuronides at lower affinity, as indicated by Km values over 100 μM. Interestingly, the MRP2-mediated transport of androsterone and epitestosterone glucuronides was best described by sigmoidal kinetics. The inability of BCRP to transport any of the androgen glucuronides investigated is drastically different from its highly active transport of several estrogen conjugates. Our results explain the transporter-mediated disposition of androgen glucuronides in humans, and shed light on differences between the human efflux transporters MRP2, MRP3, MRP4, BCRP and MDR1., Competing Interests: Declaration of Competing Interest None., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
26. Quantitative Protein Expression in the Human Retinal Pigment Epithelium: Comparison Between Apical and Basolateral Plasma Membranes With Emphasis on Transporters.
- Author
-
Hellinen L, Sato K, Reinisalo M, Kidron H, Rilla K, Tachikawa M, Uchida Y, Terasaki T, and Urtti A
- Subjects
- Biological Transport, Blotting, Western, Cell Adhesion, Cells, Cultured, Humans, Retinal Pigment Epithelium embryology, Carrier Proteins metabolism, Cell Membrane metabolism, Proteomics methods, Retinal Pigment Epithelium metabolism
- Abstract
Purpose: Retinal pigment epithelium (RPE) limits the xenobiotic entry from the systemic blood stream to the eye. RPE surface transporters can be important in ocular drug distribution, but it has been unclear whether they are expressed on the apical, basal, or both cellular surfaces. In this paper, we provide quantitative comparison of apical and basolateral RPE surface proteomes., Methods: We separated the apical and basolateral membranes of differentiated human fetal RPE (hfRPE) cells by combining apical membrane peeling and sucrose density gradient centrifugation. The membrane fractions were analyzed with quantitative targeted absolute proteomics (QTAP) and sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) to reveal the membrane protein localization on the RPE cell surfaces. We quantitated 15 transporters in unfractionated RPE cells and scaled their expression to tissue level., Results: Several proteins involved in visual cycle, cell adhesion, and ion and nutrient transport were expressed on the hfRPE plasma membranes. Most drug transporters showed similar abundance on both RPE surfaces, whereas large neutral amino acids transporter 1 (LAT1), p-glycoprotein (P-gp), and monocarboxylate transporter 1 (MCT1) showed modest apical enrichment. Many solute carriers (SLC) that are potential prodrug targets were present on both cellular surfaces, whereas putative sodium-coupled neutral amino acid transporter 7 (SNAT7) and riboflavin transporter (RFT3) were enriched on the basolateral and sodium- and chloride-dependent neutral and basic amino acid transporter (ATB0+) on the apical membrane., Conclusions: Comprehensive quantitative information of the RPE surface proteomes was reported for the first time. The scientific community can use the data to further increase understanding of the RPE functions. In addition, we provide insights for transporter protein localization in the human RPE and the significance for ocular pharmacokinetics.
- Published
- 2019
- Full Text
- View/download PDF
27. Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters.
- Author
-
Järvinen E, Sjöstedt N, Koenderink JB, Kidron H, and Finel M
- Subjects
- ATP Binding Cassette Transporter, Subfamily B metabolism, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Biological Transport, Glucuronides metabolism, Humans, Liver metabolism, Multidrug Resistance-Associated Protein 2, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism, ATP-Binding Cassette Transporters metabolism, Cotinine analogs & derivatives, Cotinine metabolism, Hepatocytes metabolism, Nicotine metabolism
- Abstract
Nicotine is the addiction causing alkaloid in tobacco, and it is used in smoking cessation therapies. Although the metabolic pathways of nicotine are well known and mainly occur in the liver, the transport of nicotine and its metabolites is poorly characterized. The highly hydrophilic nature and urinary excretion of nicotine glucuronide metabolites indicate that hepatic basolateral efflux transporters mediate their excretion. We aimed here to find the transporters responsible for the hepatic excretion of nicotine, cotinine and trans-3'-hydroxycotinine (OH-cotinine) glucuronides. To this end, we tested their transport by multidrug resistance-associated proteins 1 (MRP1, ABCC1) and MRP3-6 (ABCC3-6), which are located on the basolateral membranes of hepatocytes, as well as MRP2 (ABCC2), breast cancer resistance protein (BCRP, ABCG2) and multidrug resistance protein 1 (MDR1, P-gp, ABCB1) that are expressed in the apical membranes of these cells. ATP-dependent transport of these glucuronides was evaluated in inside-out membrane vesicles expressing the transporter of interest. In addition, potential interactions of both the glucuronides and parent compounds with selected transporters were tested by inhibition assays. Considerable ATP-dependent transport was observed only for OH-cotinine glucuronide by MRP3. The kinetics of this transport activity was characterized, resulting in an estimated K
m value of 895 µmol/L. No significant transport was found for nicotine or cotinine glucuronides by any of the tested transporters at either 5 or 50 µmol/L substrate concentration. Furthermore, neither nicotine, cotinine nor OH-cotinine inhibited MRP2-4, BCRP or MDR1. In this study, we directly examined, for the first time, efflux transport of the three hydrophilic nicotine glucuronide metabolites by the major human hepatic efflux transporters. Despite multiple transporters studied here, our results indicate that an unknown transporter may be responsible for the hepatic excretion of nicotine and cotinine glucuronides., (© 2019 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).)- Published
- 2019
- Full Text
- View/download PDF
28. Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation.
- Author
-
Ramsay E, Hagström M, Vellonen KS, Boman S, Toropainen E, Del Amo EM, Kidron H, Urtti A, and Ruponen M
- Subjects
- Animals, Biological Transport physiology, Biological Transport, Active physiology, Blood-Retinal Barrier metabolism, Cattle, Choroid metabolism, Intravitreal Injections, Metabolic Clearance Rate physiology, Permeability, Pharmaceutical Preparations metabolism, Posterior Eye Segment metabolism, Retina metabolism, Retinal Pigment Epithelium metabolism
- Abstract
Retinal pigment epithelium (RPE) is a major part of blood-retinal barrier that affects drug elimination from the vitreous to the blood and drug distribution from blood circulation into the eye. Even though drug clearance from the vitreous has been well studied, the role of RPE in the process has not been quantified. The aim of this work was to study the role of RPE clearance (CL
RPE ) as part of drug elimination from the vitreous and ocular drug distribution from the systemic blood circulation. We determined the bidirectional permeability of eight small molecular weight drugs and bevacizumab antibody across isolated bovine RPE-choroid. Permeability of small molecules was 10-6 -10-5 cm/s showing 13-15 fold range of outward and inward permeation, while permeability of bevacizumab was lower by 2-3 orders of magnitude. Most small molecular weight drugs showed comparable outward (vitreous-to-choroid) and inward (choroid-to-vitreous) permeability across the RPE-choroid, except ciprofloxacin and ketorolac that had an over 6 and 14-fold higher outward than inward permeability, respectively, possibly indicating active transport. Six of seven tested small molecular weight drugs had outward CLRPE values that were comparable with their intravitreal clearance (CLIVT ) values (0.84-2.6 fold difference). On the contrary, bevacizumab had an outward CLRPE that was only 3.5% of the CLIVT , proving that its main route of elimination (after intravitreal injection) is not RPE permeation. Experimental values were used in pharmacokinetic simulations to assess the role of the RPE in drug transfer from the systemic blood circulation to the vitreous (CLBV ). We conclude that for small molecular weight drugs the RPE is an important route in drug transfer between the vitreal cavity and blood, whereas it effectively hinders the movement of bevacizumab from the vitreous to the systemic circulation., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
29. Enantiospecific Pharmacogenomics of Fluvastatin.
- Author
-
Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvärinen M, Tapaninen T, Backman JT, and Niemi M
- Subjects
- Area Under Curve, Half-Life, Humans, Pharmacogenetics, Polymorphism, Single Nucleotide, Anticholesteremic Agents chemistry, Anticholesteremic Agents pharmacokinetics, Cytochrome P-450 CYP2C9 genetics, Fluvastatin chemistry, Fluvastatin pharmacokinetics, Liver-Specific Organic Anion Transporter 1 genetics
- Abstract
The aim of this study was to investigate how variability in multiple genes related to pharmacokinetics affects fluvastatin exposure. We determined fluvastatin enantiomer pharmacokinetics and sequenced 379 pharmacokinetic genes in 200 healthy volunteers. CYP2C9*3 associated with significantly increased area under the plasma concentration-time curve (AUC) of both 3R,5S-fluvastatin and 3S,5R-fluvastatin (by 67% and 94% per variant allele copy, P = 3.77 × 10
-9 and P = 3.19 × 10-12 ). In contrast, SLCO1B1 c.521T>C associated with increased AUC of active 3R,5S-fluvastatin only (by 34% per variant allele copy; P = 8.15 × 10-8 ). A candidate gene analysis suggested that CYP2C9*2 also affects the AUC of both fluvastatin enantiomers and that SLCO2B1 single-nucleotide variations may affect the AUC of 3S,5R-fluvastatin. Thus, SLCO transporters have enantiospecific effects on fluvastatin pharmacokinetics in humans. Genotyping of both CYP2C9 and SLCO1B1 may be useful in predicting fluvastatin efficacy and myotoxicity., (© 2019 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.)- Published
- 2019
- Full Text
- View/download PDF
30. Endogenous, cholesterol-activated ATP-dependent transport in membrane vesicles from Spodoptera frugiperda cells.
- Author
-
Sjöstedt N, Salminen TA, and Kidron H
- Subjects
- ATP-Binding Cassette Transporters chemistry, ATP-Binding Cassette Transporters genetics, Amino Acid Sequence, Animals, Estradiol pharmacology, Estrone pharmacology, Phylogeny, Quinidine pharmacology, Sequence Alignment, Sf9 Cells, Spodoptera, ATP-Binding Cassette Transporters metabolism, Cholesterol pharmacology, Estradiol analogs & derivatives, Estrone analogs & derivatives, Fluoresceins pharmacology, Quinidine analogs & derivatives
- Abstract
Transport proteins of the ATP-binding cassette (ABC) family are found in all kingdoms of life. In humans, several ABC efflux transporters play a role in drug disposition and excretion. Therefore, in vitro methods have been developed to characterize the substrate and inhibitor properties of drugs with respect to these transporters. In the vesicular transport assay, transport is studied using inverted membrane vesicles produced from transporter overexpressing cell lines of both mammalian and insect origin. Insect cell expression systems benefit from a higher expression compared to background, but are not as well characterized as their mammalian counterparts regarding endogenous transport. Therefore, the contribution of this transport in the assay might be underappreciated. In this study, endogenous transport in membrane vesicles from Spodoptera frugiperda -derived Sf9 cells was characterized using four typical substrates of human ABC transporters: 5(6)-carboxy-2,'7'-dichlorofluorescein (CDCF), estradiol-17β-glucuronide, estrone sulfate and N-methyl-quinidine. Significant ATP-dependent transport was observed for three of the substrates with cholesterol-loading of the vesicles, which is sometimes used to improve the activity of human transporters expressed in Sf9 cells. The highest effect of cholesterol was on CDCF transport, and this transport in the cholesterol-loaded Sf9 vesicles was time and concentration dependent with a K
m of 8.06 ± 1.11 μM. The observed CDCF transport was inhibited by known inhibitors of human ABCC transporters, but not by ABCB1 and ABCG2 inhibitors verapamil and Ko143, respectively. Two candidate genes for ABCC-type transporters in the S. frugiperda genome (SfABCC2 and SfABCC3) were identified based on sequence analysis as a hypothesis to explain the observed endogenous ABCC-type transport in Sf9 vesicles. Although further studies are needed to verify the role of SfABCC2 and SfABCC3 in Sf9 vesicles, the findings of this study highlight the need to carefully characterize background transport in Sf9 derived membrane vesicles to avoid false positive substrate findings for human ABC transporters studied with this overexpression system., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
31. Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments.
- Author
-
Rimpelä AK, Kiiski I, Deng F, Kidron H, and Urtti A
- Abstract
Biologicals are important ocular drugs that are be delivered using monthly and bimonthly intravitreal injections to treat retinal diseases, such as age-related macular degeneration. Long acting delivery systems are needed for prolongation of their dosing interval. Intravitreal biologicals are eliminated from the eye via the aqueous humor outflow. Thus, the anterior and posterior segments are exposed to the drug. We utilized a kinetic simulation model to estimate protein drug concentrations in the vitreous and aqueous humor after bolus injection and controlled release administration to the vitreous. The simulations predicted accurately the experimental levels of 5 biologicals in the vitreous and aqueous humor. The good match between the simulations and experimental data demonstrated almost complete anterior segment bioavailability, and major dose sparing with ocular controlled release systems. Overall, the model is a useful tool in the design of intraocular delivery of biologicals.
- Published
- 2018
- Full Text
- View/download PDF
32. Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells.
- Author
-
Rimpelä AK, Hagström M, Kidron H, and Urtti A
- Subjects
- Animals, Biological Transport, Cell Line, Chloroquine pharmacology, Diclofenac pharmacology, Humans, Methotrexate pharmacology, Propranolol pharmacology, Swine, Timolol pharmacology, Epithelial Cells metabolism, Melanins metabolism, Molecular Targeted Therapy, Retinal Pigment Epithelium cytology
- Abstract
Melanin binding affects drug distribution and retention in pigmented ocular tissues, thereby affecting drug response, duration of activity and toxicity. Therefore, it is a promising possibility for drug targeting and controlled release in the pigmented cells and tissues. Intracellular unbound drug concentrations determine pharmacological and toxicological actions, but analyses of unbound vs. total drug concentrations in pigmented cells are lacking. We studied intracellular binding and cellular drug uptake in pigmented retinal pigment epithelial cells and in non-pigmented ARPE-19 cells with five model drugs (chloroquine, propranolol, timolol, diclofenac, methotrexate). The unbound drug fractions in pigmented cells were 0.00016-0.73 and in non-pigmented cells 0.017-1.0. Cellular uptake (i.e. distribution ratio Kp), ranged from 1.3 to 6300 in pigmented cells and from 1.0 to 25 in non-pigmented cells. Values for intracellular bioavailability, F
ic , were similar in both cells types (although larger variation in pigmented cells). In vitro melanin binding parameters were used to predict intracellular unbound drug fraction and cell uptake. Comparison of predictions with experimental data indicates that other factors (e.g. ion-trapping, lipophilicity-related binding to other cell components) also play a role. Melanin binding is a major factor that leads to cellular uptake and unbound drug fractions of a range of 3-4 orders of magnitude indicating that large reservoirs of melanin bound drug can be generated in the cells. Understanding melanin binding has important implications on retinal drug targeting, efficacy and toxicity., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
33. Binding of Small Molecule Drugs to Porcine Vitreous Humor.
- Author
-
Rimpelä AK, Reunanen S, Hagström M, Kidron H, and Urtti A
- Subjects
- Administration, Ophthalmic, Animals, Chromatography, High Pressure Liquid, Models, Animal, Retinal Diseases drug therapy, Swine, Tandem Mass Spectrometry, Pharmacokinetics, Vitreous Body metabolism
- Abstract
Pharmacokinetics in the posterior eye segment has therapeutic implications due to the importance of retinal diseases in ophthalmology. In principle, drug binding to the components of the vitreous, such as proteins, collagen, or glycosaminoglycans, could prolong ocular drug retention and modify levels of pharmacologically active free drug in the posterior eye segment. Since drug binding in the vitreous has been investigated only sparsely, we studied vitreal drug binding of 35 clinical small molecule drugs. Isolated homogenized porcine vitreous and the drugs were placed in a two-compartment dialysis system that was used to separate the bound and unbound drug. Free drug concentrations and binding percentages were quantitated using LC-MS/MS. Drug binding levels varied between 21 and 74% in the fresh vitreous and 0 and 64% in the frozen vitreous. The vitreal binding percentages did not correlate with those in plasma. Our data-based pharmacokinetic simulations suggest that vitreal binding of small molecule drugs has only a modest influence on the AUC of free drug or drug half-life in the vitreous. Therefore, it is likely that vitreal binding is not a major reason for interindividual variability in ocular drug responses or drug-drug interactions.
- Published
- 2018
- Full Text
- View/download PDF
34. Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP.
- Author
-
Järvinen E, Deng F, Kidron H, and Finel M
- Subjects
- Biological Transport, Humans, Multidrug Resistance-Associated Protein 2, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Estrogens metabolism, Estrogens, Conjugated (USP) metabolism, Glucuronides metabolism, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism
- Abstract
Estrone, estradiol and estriol are endogenous human estrogens that are rapidly conjugated with glucuronic acid in both intestinal and hepatic epithelial cells. The resulting glucuronides, estrone-3-glucuronide (E
1 -G), estradiol-3- and 17-glucuronides (E2 -3G and E2 -17G), as well as estriol-3- and 16-glucuronides (E3 -3G and E3 -16G) are found in human plasma and urine. Unlike E2 -17G, the efflux transport of other estrogen glucuronides by human transporters has not yet been investigated comprehensively. We have studied the transport of E1 -G, E2 -3G, E3 -3G, E3 -16G and estrone-3-sulfate (E1 -S), another important estrogen conjugate, using the vesicular transport assay with recombinant human MRP2, MRP3, MRP4, MDR1 and BCRP that were expressed in insect cells. The transport screening assays revealed that whereas E1 -S was a good and specific substrate for BCRP, the less transporter-specific conjugates, E1 -G and E2 -3G, were still transported by BCRP at 10-fold higher rates than E1 -S. BCRP also transported E3 -16G at higher rates than the studied MRPs, while it transported E3 -3G at lower rates than MRP3. MRP2 exhibited lower or equal transport rates of E1 -G, E2 -3G, E3 -3G and E3 -16G in comparison to MRP3 and BCRP in the screening assays, mainly due to its high Km values, between 180 and 790 μM. MRP3 transported all the tested glucuronides at rather similar rates, at Km values below 20 μM, but lower Vmax values than other transporters. In the case of E3 -3G, MRP3 was the most active transporter in the screening assay. MRP4 transported only E3 -16G at considerable rates, while none of the tested estrogen conjugates was transported by MDR1 at higher rates than control vesicles. These new results, in combination with previously reported in vivo human data, stimulate our understanding on the substrate specificity and role of efflux transporters in disposition of estrogen glucuronides in humans., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
35. Implications of melanin binding in ocular drug delivery.
- Author
-
Rimpelä AK, Reinisalo M, Hellinen L, Grazhdankin E, Kidron H, Urtti A, and Del Amo EM
- Subjects
- Animals, Binding Sites, Humans, Drug Delivery Systems, Eye Diseases drug therapy, Eye Diseases metabolism, Melanins chemistry
- Abstract
Pigmented ocular tissues contain melanin within the intracellular melanosomes. Drugs bind to melanin at varying extent that ranges from no binding to extensive binding. Binding may lead to drug accumulation to the pigmented tissues and prolonged drug retention in the melanin containing cells. Therefore, melanin binding is an important feature that affects ocular drug delivery and biodistribution, but this topic has not been reviewed since 1998. In this review, we present current knowledge on ocular melanin, melanosomes and binding of drugs to pigmented cells and tissues. In vitro, in vivo and in silico methods in the field were critically evaluated, because the literature in this field can be confusing if the reader does not properly understand the methodological aspects. Literature analysis includes a comprehensive table of literature data on melanin binding of drugs. Furthermore, we aimed to give some insights beyond the current literature by making a chemical structure based classification model for melanin binding of drugs and kinetic simulations that revealed significant interplay between melanin binding and drug permeability across the melanosomal and plasma membranes. Overall, more mechanistic and systematic research is needed before the impact of melanin binding on ocular drug delivery can be properly understood and predicted., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
36. Expression, activity and pharmacokinetic impact of ocular transporters.
- Author
-
Vellonen KS, Hellinen L, Mannermaa E, Ruponen M, Urtti A, and Kidron H
- Subjects
- Animals, Biological Transport, Humans, Drug Delivery Systems, Eye metabolism, Membrane Transport Proteins metabolism, Pharmaceutical Preparations, Pharmacokinetics
- Abstract
The eye is protected by several tissues that limit the permeability and entry of potentially harmful substances, but also hamper the delivery of drugs in the treatment of ocular diseases. Active transport across the ocular barriers may affect drug distribution, but the impact of drug transporters on ocular drug delivery is not well known. We have collected and critically reviewed the literature for ocular expression and activity of known drug transporters. The review concentrates on drug transporters that have been functionally characterized in ocular tissues or primary cells and on transporters for which there is available expression data at the protein level. Species differences are highlighted, since these may explain observed inconsistencies in the influence of specific transporters on drug disposition. There is variable evidence about the pharmacokinetic role of transporters in ocular tissues. The strongest evidence for the role of active transport is available for the blood-retinal barrier. We explored the role of active transport in the cornea and blood retinal barrier with pharmacokinetic simulations. The simulations show that the active transport is important only in the case of specific parameter combinations., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
37. Long-term nutritional and gastrointestinal aspects in patients with ataxia telangiectasia.
- Author
-
Krauthammer A, Lahad A, Sarouk Y, Somech R, Nissenkorn A, Modan-Moses D, Levi-Kidron H, Sadeh-Kon T, and Weiss B
- Subjects
- Adolescent, Ataxia Telangiectasia complications, Ataxia Telangiectasia therapy, Body Height, Body Mass Index, Body Weight, Child, Child, Preschool, Cough, Deglutition Disorders epidemiology, Deglutition Disorders physiopathology, Eating, Energy Intake, Enteral Nutrition, Exercise, Female, Follow-Up Studies, Humans, Male, Respiratory Tract Infections complications, Respiratory Tract Infections epidemiology, Retrospective Studies, Young Adult, Ataxia Telangiectasia physiopathology, Gastrointestinal Tract physiopathology, Nutritional Status physiology
- Abstract
Objective: Ataxia telangiectasia (A-T) is a rare genetic disease involving multiple organs, but, to our knowledge, data on long-term gastrointestinal and nutritional involvement are scarce. The aim of this study was to longitudinally review the nutritional and gastrointestinal aspects of A-T., Methods: This was a retrospective chart review of patients followed from 1986 to 2015 at one center. Demographic, laboratory, and nutritional data were retrieved. Body mass index (BMI) values were converted to BMI Z-score (BMI-Z). Caloric intake was estimated by food diaries and compared with estimated energy requirements for sex and age with a physical activity level factor for light physical activity., Results: The study included 53 patients (28 males [53%], ages 14.6 ± 5.2 y). BMI-Z was inversely correlated with age (r = 0.48; P < 0.004). A decline below minimal BMI percentiles was observed after the age of 4 y in boys and 7 y in girls. The relative percentage of caloric intake decreased with age (r = -0.5; P < 0.002), and was positively correlated with BMI-Z (r = 0.35; P < 0.05). Presence of cough during meals was associated with recurrent lower respiratory tract infections (Fisher exact test, P < 0.01). Gastrostomy tubes were inserted in 12 patients, leading to improvement in BMI-Z from -5.1 ± 2.4 to -4 ± 2.9 (P < 0.05)., Conclusions: There is a progressive growth failure and low nutritional intake with age in patients with A-T, starting in early childhood in males, and more prominent in patients with cough and choking during meals. A proactive approach and insertion of a percutaneous gastrostomy tube as soon as the BMI-Z starts to decrease should be considered., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
38. Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts.
- Author
-
Pelkonen L, Tengvall-Unadike U, Ruponen M, Kidron H, Del Amo EM, Reinisalo M, and Urtti A
- Subjects
- Animals, Renal Dialysis, Swine, Melanins metabolism, Pharmaceutical Preparations metabolism, Retinal Pigment Epithelium metabolism
- Abstract
Melanin pigment is a negatively charged polymer found in pigmented human tissues. In the eye, iris, ciliary body, choroid and retinal pigment epithelium (RPE) are heavily pigmented. Several drug molecules are known to bind to melanin, but larger sets of drugs have not been compared often in similar test conditions. In this study, we introduce a powerful tool for screening of melanin binding. The binding of a set of 34 compounds to isolated porcine RPE melanin was determined by cassette (n-in-one) dosing in rapid equilibrium dialysis inserts and the binding was quantitated with LC-MS/MS analytics. The compounds represented large variety in melanin binding (from 8.6%, ganciclovir) to over 95% bound (ampicillin and ciprofloxacin). The data provides information on melanin binding of small molecular weight compounds that are used for ocular (e.g. brinzolamide, ganciclovir) and systemic (e.g. tizanidine, indomethacin) therapy. Interestingly, competition among compounds was seen for melanin binding and the binding did not show any correlation with plasma protein binding. These results increase the understanding of melanin binding of ocular drugs and can be further exploited to predict pharmacokinetics in the eye. Pigment binding provides an interesting option for improved drug distribution to retina and choroid that are difficult target tissues in drug delivery., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
39. Interaction of Food Additives with Intestinal Efflux Transporters.
- Author
-
Sjöstedt N, Deng F, Rauvala O, Tepponen T, and Kidron H
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, ATP-Binding Cassette Transporters metabolism, Humans, Multidrug Resistance-Associated Protein 2, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism, Food Additives metabolism, Membrane Transport Proteins metabolism
- Abstract
Breast cancer resistance protein (BCRP), multidrug resistance associated protein 2 (MRP2) and P-glycoprotein (P-gp) are ABC transporters that are expressed in the intestine, where they are involved in the efflux of many drugs from enterocytes back into the intestinal lumen. The inhibition of BCRP, MRP2, and P-gp can result in enhanced absorption and exposure of substrate drugs. Food additives are widely used by the food industry to improve the stability, flavor, and consistency of food products. Although they are considered safe for consumption, their interactions with intestinal transporters are poorly characterized. Therefore, in this study, selected food additives, including preservatives, colorants, and sweeteners, were studied in vitro for their inhibitory effects on intestinal ABC transporters. Among the studied compounds, several colorants were able to inhibit BCRP and MRP2, whereas P-gp was fairly insensitive to inhibition. Additionally, one sweetener was identified as a potent inhibitor of BCRP. Dose-response studies revealed that the IC
50 values of the inhibitors were lower than the estimated intestinal concentrations after the consumption of beverages containing food colorants. This suggests that there is potential for previously unrecognized transporter-mediated food additive-drug interactions.- Published
- 2017
- Full Text
- View/download PDF
40. Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
- Author
-
Järvinen E, Troberg J, Kidron H, and Finel M
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Animals, Biological Assay, Biological Transport, Active, Estradiol analogs & derivatives, Estradiol pharmacokinetics, Glucuronates metabolism, Humans, Hymecromone analogs & derivatives, Multidrug Resistance-Associated Protein 2, Neoplasm Proteins metabolism, Propranolol chemical synthesis, Propranolol pharmacokinetics, Pyrenes metabolism, Recombinant Proteins metabolism, Sf9 Cells, Spodoptera, Stereoisomerism, Glucuronates pharmacokinetics, Glucuronides pharmacokinetics, Hymecromone pharmacokinetics, Multidrug Resistance-Associated Proteins metabolism, Propranolol analogs & derivatives
- Abstract
Xenobiotic and endobiotic glucuronides, which are generated in hepatic and intestinal epithelial cells, are excreted via efflux transporters. Multidrug resistance proteins 2-4 (MRP2-MRP4) and the breast cancer resistance protein (BCRP) are efflux transporters that are expressed in these polarized cells, on either the basolateral or apical membranes. Their localization, along with expression levels, affects the glucuronide excretion pathways. We have studied the transport of three planar cyclic glucuronides and glucuronides of the two propranolol enantiomers, by the vesicular transport assay, using vesicles from baculovirus-infected insect cells expressing human MRP2, MRP3, MRP4, or BCRP. The transport of estradiol-17β-glucuronide by recombinant MRP2-4 and BCRP, as demonstrated by kinetic values, were within the ranges previously reported. Our results revealed high transport rates and apparent affinity of MRP4 toward the glucuronides of 4-methylumbelliferone, 1-naphthol, and 1-hydroxypyrene (K
m values of 168, 13, and 3 μM, respectively) in comparison to MRP3 (Km values of 278, 98, and 8 μM, respectively). MRP3 exhibited lower rates, but stereoselective transport of propranolol glucuronides, with higher affinity toward the R-enantiomer than the S-enantiomer (Km values 154 vs 434 μM). The glucuronide of propranolol R-enantiomer was not significantly transported by either MRP2, MRP4, or BCRP. Of the tested small glucuronides in this study, BCRP transported only 1-hydroxypyrene glucuronide, at very high rates and high apparent affinity (Vmax and Km values of 4400 pmol/mg/min and 11 μM). The transport activity of MRP2 with all of the studied small glucuronides was relatively very low, even though it transported the reference compound, estradiol-17β-glucuronide, at a high rate (Vmax = 3500 pmol/mg/min). Our results provide new information, at the molecular level, of efflux transport of the tested glucuronides, which could explain their disposition in vivo, as well as provide new tools for in vitro studies of MRP3, MRP4, and BCRP.- Published
- 2017
- Full Text
- View/download PDF
41. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
- Author
-
Sjöstedt N, van den Heuvel JJMW, Koenderink JB, and Kidron H
- Subjects
- Animals, Biological Transport, Genetic Variation, HEK293 Cells, Humans, Mutation, Polymorphism, Single Nucleotide, Sf9 Cells, Transfection, ATP Binding Cassette Transporter, Subfamily G, Member 2 genetics, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Neoplasm Proteins genetics, Neoplasm Proteins metabolism
- Abstract
Purpose: To study the function and expression of nine naturally occurring single-nucleotide polymorphisms (G406R, F431L, S441N, P480L, F489L, M515R, L525R, A528T and T542A) that are predicted to reside in the transmembrane regions of the ABC transporter ABCG2., Methods: The transport activity of the variants was tested in inside-out membrane vesicles from Sf9 insect and human derived HEK293 cells overexpressing ABCG2. Lucifer Yellow and estrone sulfate were used as probe substrates of activity. The expression levels and cellular localization of the variants was compared to the wild-type ABCG2 by western blotting and immunofluorescence microscopy., Results: All studied variants of ABCG2 displayed markedly decreased transport in both Sf9-ABCG2 and HEK293-ABCG2 vesicles. Impaired transport could be explained for some variants by altered expression levels and cellular localization. Moreover, the destructive effect on transport activity of variants G406R, P480L, M515R and T542A is, to our knowledge, reported for the first time., Conclusions: These results indicate that the transmembrane region of ABCG2 is sensitive to amino acid substitution and that patients harboring these ABCG2 variant forms could suffer from unexpected pharmacokinetic events of ABCG2 substrate drugs or have an increased risk for diseases such as gout where ABCG2 is implicated.
- Published
- 2017
- Full Text
- View/download PDF
42. A structure-activity relationship study of ABCC2 inhibitors.
- Author
-
Wissel G, Deng F, Kudryavtsev P, Ghemtio L, Wipf P, Xhaard H, and Kidron H
- Subjects
- Biological Transport, Fluoresceins chemistry, Models, Molecular, Multidrug Resistance-Associated Protein 2, Structure-Activity Relationship, Multidrug Resistance-Associated Proteins antagonists & inhibitors
- Abstract
Multidrug resistance associated protein 2 (MRP2/ABCC2) is a membrane transport protein that can potentially affect the disposition of many substrate drugs and their metabolites. Recently, we studied the interaction of a library of 432 compounds with ABCC2, and the structure-activity relationship (SAR) of a subset of 64 compounds divided into four scaffolds (Wissel, G. et al., 2015. Bioorg Med Chem., 23(13), pp.3513-25). We have now expanded this test set by investigating 114 new compounds, of which 71 are representative of the previous four scaffolds and 43 compounds belong to a new scaffold. Interaction with ABCC2 was assessed by measuring the compounds effect on 5(6)-carboxy-2',7'-dichlorofluorescein transport in the vesicular transport assay. In line with our previous study, we observed that anionic charge is not essential for inhibition of ABCC2 transport, even though it often increases the inhibitory activity within the analogue series. Additionally, we found that halogen substitutions often increase the inhibitory activity. The results confirm the importance of structural features such as aromaticity and lipophilicity for ABCC2 inhibitory activity., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
43. LC-MS/MS Based Quantitation of ABC and SLC Transporter Proteins in Plasma Membranes of Cultured Primary Human Retinal Pigment Epithelium Cells and Immortalized ARPE19 Cell Line.
- Author
-
Pelkonen L, Sato K, Reinisalo M, Kidron H, Tachikawa M, Watanabe M, Uchida Y, Urtti A, and Terasaki T
- Subjects
- Blood-Retinal Barrier metabolism, Carrier Proteins metabolism, Cell Line, Chromatography, Liquid methods, Humans, Proteomics methods, Sodium-Potassium-Exchanging ATPase metabolism, Tandem Mass Spectrometry methods, Up-Regulation physiology, ATP-Binding Cassette Transporters metabolism, Cell Membrane metabolism, Pigment Epithelium of Eye metabolism, Retinal Pigment Epithelium metabolism, Solute Carrier Proteins metabolism
- Abstract
The retinal pigment epithelium (RPE) forms the outer blood-retinal barrier between neural retina and choroid. The RPE has several important vision supporting functions, such as transport mechanisms that may also modify pharmacokinetics in the posterior eye segment. Expression of plasma membrane transporters in the RPE cells has not been quantitated. The aim of this study was to characterize and compare transporter protein expression in the ARPE19 cell line and hfRPE (human fetal RPE) cells by using quantitative targeted absolute proteomics (QTAP). Among 41 studied transporters, 16 proteins were expressed in hfRPE and 13 in ARPE19 cells. MRP1, MRP5, GLUT1, 4F2hc, TAUT, CAT1, LAT1, and MATE1 proteins were detected in both cell lines within 4-fold differences. MPR7, OAT2 and RFC1 were detected in the hfRPE cells, but their expression levels were below the limit of quantification in ARPE19 cells. PCFT was detected in both studied cell lines, but the expression was over 4-fold higher in hfRPE cells. MCT1, MCT4, MRP4, and Na
+ /K+ ATPase were upregulated in the ARPE19 cell line showing over 4-fold differences in the quantitative expression values. Expression levels of 25 transporters were below the limit of quantification in both cell models. In conclusion, we present the first systematic and quantitative study on transporter protein expression in the plasma membranes of ARPE19 and hfRPE cells. Overall, transporter expression in the ARPE19 and hfRPE cells correlated well and the absolute expression levels were similar, but not identical. The presented quantitative expression levels could be a useful basis for further studies on drug permeation in the outer blood-retinal barrier.- Published
- 2017
- Full Text
- View/download PDF
44. Pharmacokinetic aspects of retinal drug delivery.
- Author
-
Del Amo EM, Rimpelä AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, Schmitt M, Pelkonen L, Bhattacharya M, Richardson D, Subrizi A, Turunen T, Reinisalo M, Itkonen J, Toropainen E, Casteleijn M, Kidron H, Antopolsky M, Vellonen KS, Ruponen M, and Urtti A
- Subjects
- Animals, Drug Delivery Systems, Humans, Intravitreal Injections, Retinal Diseases metabolism, Tissue Distribution, Angiogenesis Inhibitors administration & dosage, Angiogenesis Inhibitors pharmacokinetics, Retina metabolism, Retinal Diseases drug therapy
- Abstract
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory., (Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
45. Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives.
- Author
-
Sjöstedt N, Holvikari K, Tammela P, and Kidron H
- Subjects
- Animals, Biological Transport drug effects, Breast Neoplasms metabolism, Cell Line, DNA, Complementary metabolism, Flavonoids chemistry, Flavonoids pharmacology, Food-Drug Interactions physiology, Gallic Acid analogs & derivatives, Gallic Acid chemistry, Humans, Masoprocol chemistry, Membrane Transport Proteins metabolism, Multidrug Resistance-Associated Protein 2, Sf9 Cells, ATP Binding Cassette Transporter, Subfamily G, Member 2 antagonists & inhibitors, Biological Products pharmacology, Breast Neoplasms diet therapy, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Neoplasm Proteins antagonists & inhibitors
- Abstract
The food and dietary supplements we consume contain a wide variety of plant secondary metabolites and other compounds, which, like drugs, can be absorbed, metabolized, distributed, and excreted from the body. In the intestine, these compounds can interact with transport proteins such as the multidrug resistance associated protein 2 (MRP2, ABCC2) and the breast cancer resistance protein (BCRP, ABCG2) that regulate the absorption of drugs and other compounds. Inhibition of these transporters by dietary components could lead to increased exposure and adverse effects of concomitantly administered drugs. Therefore, we screened a library of 124 natural compounds and their derivatives using the vesicular transport assay to evaluate their inhibitory potential on MRP2 and BCRP. Of the library compounds, 36% were identified as BCRP inhibitors, whereas the number was only 3.2% for MRP2. BCRP inhibitors are described by higher molecular weight, number of rings, aromaticity, and LogD
7.4 than noninhibitors. IC50 values were measured for six dual inhibitors, among which three novel inhibitors, gossypin, nordihydroguaiaretic acid, and octyl gallate, were identified. Our results confirm that flavonoids are avid inhibitors of BCRP, and flavones and flavonols appear to be important subclasses of flavonoids for this inhibition. The strong inhibition of BCRP transport by some compounds suggests that their presence at high levels in the diet could cause food-drug interactions, but this seems to be a minor cause of concern for MRP2.- Published
- 2017
- Full Text
- View/download PDF
46. General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.
- Author
-
Deng F, Ranta VP, Kidron H, and Urtti A
- Subjects
- Administration, Ophthalmic, Animals, Aqueous Humor metabolism, Biological Availability, Chemistry, Pharmaceutical, Drug Liberation, Epithelium, Corneal metabolism, Excipients, Fluorometholone chemistry, Fluorometholone pharmacokinetics, Ocular Absorption, Ophthalmic Solutions, Pilocarpine chemistry, Pilocarpine pharmacokinetics, Rabbits, Computer Simulation, Fluorometholone administration & dosage, Models, Biological, Pilocarpine administration & dosage
- Abstract
Purpose: In ocular drug development, an early estimate of drug behavior before any in vivo experiments is important. The pharmacokinetics (PK) and bioavailability depend not only on active compound and excipients but also on physicochemical properties of the ocular drug formulation. We propose to utilize PK modelling to predict how drug and formulational properties affect drug bioavailability and pharmacokinetics., Methods: A physiologically relevant PK model based on the rabbit eye was built to simulate the effect of formulation and physicochemical properties on PK of pilocarpine solutions and fluorometholone suspensions. The model consists of four compartments: solid and dissolved drug in tear fluid, drug in corneal epithelium and aqueous humor. Parameter values and in vivo PK data in rabbits were taken from published literature., Results: The model predicted the pilocarpine and fluorometholone concentrations in the corneal epithelium and aqueous humor with a reasonable accuracy for many different formulations. The model includes a graphical user interface that enables the user to modify parameters easily and thus simulate various formulations., Conclusions: The model is suitable for the development of ophthalmic formulations and the planning of bioequivalence studies.
- Published
- 2016
- Full Text
- View/download PDF
47. The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay.
- Author
-
Deng F, Sjöstedt N, and Kidron H
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Animals, Estradiol analogs & derivatives, Estradiol metabolism, Fluoresceins metabolism, Humans, Kinetics, Multidrug Resistance-Associated Protein 2, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism, Sf9 Cells, ATP Binding Cassette Transporter, Subfamily G, Member 2 genetics, Biological Transport drug effects, Multidrug Resistance-Associated Proteins genetics, Neoplasm Proteins genetics, Serum Albumin pharmacology
- Abstract
The ABC transporters multidrug resistance associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) are of interest in drug development, since they affect the pharmacokinetics of several drugs. Membrane vesicle transport assays are widely used to study interactions with these proteins. Since albumin has been found to affect the kinetics of metabolic enzymes in similar membrane preparations, we investigated whether albumin affects the kinetic parameters of efflux transport. We found that albumin increased the Vmax of 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) and estradiol-17-β-D-glucuronide uptake into MRP2 vesicles in the presence of 0.1% bovine serum albumin (BSA) by 2 and 1.5-fold, respectively, while BSA increased Lucifer yellow uptake by 30% in BCRP vesicles. Km values increased slightly, but the change was not statistically significant. The effect of BSA on substrate uptake was dependent on the vesicle amount, while increasing BSA concentration did not significantly improve substrate uptake. These results indicate a minor effect of albumin on MRP2 and BCRP, but it should be considered if albumin is added to transporter assays for example as a solubilizer, since the effect may be substrate or transporter specific., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
48. Drug Distribution to Retinal Pigment Epithelium: Studies on Melanin Binding, Cellular Kinetics, and Single Photon Emission Computed Tomography/Computed Tomography Imaging.
- Author
-
Rimpelä AK, Schmitt M, Latonen S, Hagström M, Antopolsky M, Manzanares JA, Kidron H, and Urtti A
- Subjects
- Animals, Cells, Cultured, Chloroquine metabolism, Eye metabolism, Hydrogen-Ion Concentration, Iodine Radioisotopes, Kinetics, Methotrexate metabolism, Nadolol metabolism, Protein Binding, Rats, Swine, Timolol metabolism, Melanins metabolism, Retinal Pigment Epithelium metabolism, Single Photon Emission Computed Tomography Computed Tomography methods
- Abstract
Melanin binding is known to affect the distribution and elimination of ocular drugs. The purpose of this study was to evaluate if the extent of drug uptake to primary retinal pigment epithelial (RPE) cells could be estimated based on in vitro binding studies with isolated melanin and evaluate the suitability of single photon emission computed tomography/computed tomography (SPECT/CT) in studying pigment binding in vivo with pigmented and albino rats. Binding of five compounds, basic molecules timolol, chloroquine, and nadolol and acidic molecules methotrexate and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF), was studied using isolated melanin from porcine choroid-RPE at pH 5.0 and 7.4. The uptake to primary porcine RPE cells was studied with timolol, chloroquine, methotrexate, and CDCF. The cell study setting was modeled using parameters from the in vitro binding study. In vivo kinetics of 3-[I-123]-iodochloroquine was studied by the SPECT/CT method in albino and pigmented rats. All basic compounds bound to melanin at both pH values, whereas the acidic compounds bound more at pH 5.0 than at pH 7.4. The basic compounds (chloroquine, timolol) showed significant cellular uptake, unlike the acidic compounds (methotrexate, CDCF). On the basis of the modeling, melanin binding was a major factor governing the overall drug distribution to the RPE cells. Likewise, melanin binding explained distribution of 3-[I-123]-iodochloroquine in the pigmented RPE, whereas drug accumulation was not seen in the albino rat. This study demonstrates the suitability of noninvasive SPECT/CT imaging in monitoring ocular melanin binding in vivo. These studies are a useful step toward understanding the pharmacokinetic impact of melanin binding.
- Published
- 2016
- Full Text
- View/download PDF
49. Isolation of Intact and Functional Melanosomes from the Retinal Pigment Epithelium.
- Author
-
Pelkonen L, Reinisalo M, Morin-Picardat E, Kidron H, and Urtti A
- Subjects
- Animals, Melanocytes ultrastructure, Microscopy, Electron, Transmission, Swine, Cell Separation methods, Melanosomes ultrastructure, Retinal Pigment Epithelium ultrastructure
- Abstract
Melanosomes of retinal pigment epithelium (RPE) have many vision supporting functions. Melanosome research would benefit from a method to isolate pure and characterized melanosomes. Sucrose gradient centrifugation is the most commonly used method for isolation of RPE melanosomes, but the isolated products are insufficiently characterized and their quality is unclear. Here we introduce a new gentle method for fractionation of porcine RPE that produces intact functional melanosomes with minimal cross-contamination from other cell organelles. The characterization of isolated organelles was conducted with several methods confirming the purity of the isolated melanosomal fraction (transmission electron microscopy, immunoblotting) and presence of the melanosomal membrane (fluorescence staining of melanosomal membrane, zeta potential measurement). We demonstrate that our isolation method produces RPE melanosomes with the ability to generate free phosphate (Pi) from ATP thereby proving that many membrane proteins remain functional after isolation. The isolated porcine RPE melanosomes represented V-type H+ATPase activity that was demonstrated with bafilomycin A1, a specific V-ATPase inhibitor. We anticipate that the isolation method described here can easily be optimized for the isolation of stage IV melanosomes from other pigmented cell types and tissues., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
50. Predictive Modeling of Ocular Pharmacokinetics and Adverse Effects.
- Author
-
Ghemtio L, Xhaard H, Urtti A, and Kidron H
- Subjects
- Animals, Blood-Retinal Barrier drug effects, Corneal Diseases pathology, Drug Delivery Systems, Humans, Models, Molecular, Ophthalmic Solutions administration & dosage, Quantitative Structure-Activity Relationship, Corneal Diseases drug therapy, Ophthalmic Solutions adverse effects, Ophthalmic Solutions pharmacokinetics
- Abstract
Treatment of ocular disorders is a challenge due to the difficulty of delivering drugs to the target tissues within the eye at sufficient concentrations to produce a therapeutic effect. The cornea and the blood-retinal barrier, comprising of the retinal pigment epithelium and the retinal capillaries, are the main barriers for delivering drugs to treat diseases in the anterior and posterior parts of the eye, respectively. The eye has a rich blood supply and relatively small mass, and drugs can distribute from the systemic blood circulation to the choroid through the fenestrated choroidal blood vessels, but further permeation into the eye is limited by the blood-retinal barrier. Computational prediction of the ocular pharmacokinetics of drugs can help improve drug delivery and predict ocular adverse effects resulting from ocular or systemic drugs. Computational models predicting ocular adverse effects of drugs are still scarce, even though prediction of eye irritation and corrosion of chemicals has been well studied as a consequence of recent European Union legislation. Predictive modeling of adverse effects suffers from the wide distribution of data resources, but databases that integrate data on adverse effects, drugs, targets and other related biological data from different sources offer improved prospects for predictive modeling., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.